KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Hims & Hers Health (HIMS) Shares Outstanding (2019 - 2025)

Hims & Hers Health's Shares Outstanding history spans 7 years, with the latest figure at $227.2 million for Q4 2025.

  • For Q4 2025, Shares Outstanding rose 2.9% year-over-year to $227.2 million; the TTM value through Dec 2025 reached $227.2 million, up 2.9%, while the annual FY2025 figure was $227.2 million, 2.9% up from the prior year.
  • Shares Outstanding for Q4 2025 was $227.2 million at Hims & Hers Health, roughly flat from $227.5 million in the prior quarter.
  • Across five years, Shares Outstanding topped out at $227.5 million in Q3 2025 and bottomed at $191.4 million in Q1 2021.
  • The 5-year median for Shares Outstanding is $211.4 million (2023), against an average of $212.1 million.
  • The largest annual shift saw Shares Outstanding surged 291.4% in 2021 before it grew 1.67% in 2023.
  • A 5-year view of Shares Outstanding shows it stood at $204.8 million in 2021, then grew by 1.78% to $208.4 million in 2022, then grew by 2.42% to $213.5 million in 2023, then increased by 3.45% to $220.8 million in 2024, then increased by 2.9% to $227.2 million in 2025.
  • Per Business Quant, the three most recent readings for HIMS's Shares Outstanding are $227.2 million (Q4 2025), $227.5 million (Q3 2025), and $225.8 million (Q2 2025).